Clinical trial
Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)
NCT02406222 is registered in ClinicalTrials.gov with University of Leeds as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)
- Lead sponsor
- University of Leeds
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- March 31, 2016
- Completion date
- June 30, 2025
- Enrollment
- 124 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.